{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:36:27Z","timestamp":1793421387473,"version":"4.5.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":185,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic liver disease presents a significant global health burden, characterized by several etiologies, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), chronic hepatitis B virus infection, and chronic hepatitis C virus infection. This review explored current epidemiological trends and projections for each etiology, looking into their respective burdens and challenges. MASLD, formerly known as nonalcoholic fatty liver disease, is the most prevalent cause of chronic liver disease, and its global incidence and prevalence are steadily rising. ALD, fueled by increased alcohol consumption, is also on the rise, with concerning implications for future mortality rates. Chronic hepatitis B and C infections remain major public health concerns, particularly in specific regions of the world, necessitating concerted efforts for screening and treatment. The coronavirus disease 2019 (COVID-19) pandemic has impacted the epidemiology of chronic liver disease, exacerbating mortality rates and disrupting healthcare services. Mental health issues arising from the pandemic further complicate the treatment of chronic liver disease, making comprehensive healthcare strategies essential. Despite advancements in treatment, chronic liver disease continues to impose a substantial economic burden, emphasizing the importance of preventive measures and early intervention. In conclusion, ongoing surveillance and research efforts are crucial for understanding and addressing the evolving landscape of chronic liver disease. Comprehensive strategies that encompass prevention, screening, and treatment of its different etiologies are essential for mitigating its impact and improving patient outcomes.<\/jats:p>","DOI":"10.1093\/gastro\/goae069","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T08:26:35Z","timestamp":1719217595000},"source":"Crossref","is-referenced-by-count":70,"title":["Current epidemiology of chronic liver disease"],"prefix":"10.1093","volume":"12","author":[{"given":"Richie","family":"Manikat","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1919-6800","authenticated-orcid":false,"given":"Donghee","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2024062408262302200_goae069-B1","doi-asserted-by":"crossref","first-page":"e54\u20136","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5009\/gnl20127","article-title":"Recent epidemiology of nonalcoholic fatty liver disease","volume":"15","author":"Murag","year":"2021","journal-title":"Gut Liver"},{"key":"2024062408262302200_goae069-B5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B6","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","article-title":"Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease","volume":"29","author":"Konyn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2024062408262302200_goae069-B7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.cgh.2020.08.017","article-title":"Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017-2018","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B12","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024062408262302200_goae069-B13","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024062408262302200_goae069-B14","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/HEP.0000000000000383","article-title":"Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019","volume":"78","author":"Hartmann","year":"2023","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17849","article-title":"Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States","volume":"59","author":"Gawrieh","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2024062408262302200_goae069-B17","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.32774","article-title":"Geographical similarity and differences in the burden and genetic predisposition of NAFLD","volume":"77","author":"Yip","year":"2023","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1194\/jlr.M048777","article-title":"The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis","volume":"56","author":"Shen","year":"2015","journal-title":"J Lipid Res"},{"key":"2024062408262302200_goae069-B19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"2024062408262302200_goae069-B20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2024062408262302200_goae069-B21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejim.2023.09.024","article-title":"Chronic liver disease-related mortality during the COVID-19 pandemic","volume":"118","author":"Kim","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2024062408262302200_goae069-B23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2021.09.054","article-title":"Onset and frequency of depression in post-COVID-19 syndrome: a systematic review","volume":"144","author":"Renaud-Charest","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2024062408262302200_goae069-B24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jad.2023.02.101","article-title":"Association between depression and metabolic dysfunction-associated fatty liver disease\/significant fibrosis","volume":"329","author":"Kim","year":"2023","journal-title":"J Affect Disord"},{"key":"2024062408262302200_goae069-B25","doi-asserted-by":"crossref","first-page":"e14087","DOI":"10.1111\/eci.14087","article-title":"Depression in nonalcoholic fatty liver disease and all-cause\/cause-specific mortality","volume":"54","author":"Kim","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2024062408262302200_goae069-B26","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.jhep.2023.09.014","article-title":"Metabolic dysfunction-associated steatotic liver disease and all-cause\/cause-specific mortality among adults in the United States","volume":"80","author":"Kim","year":"2024","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/apt.18011","article-title":"Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States","volume":"60","author":"Kim","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2024062408262302200_goae069-B28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/ADM.0000000000000767","article-title":"Alcohol consumption in response to the COVID-19 pandemic in the United States","volume":"15","author":"Barbosa","year":"2021","journal-title":"J Addict Med"},{"key":"2024062408262302200_goae069-B30","author":"Slater","year":"2022"},{"key":"2024062408262302200_goae069-B31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14309\/ajg.0000000000000380","article-title":"Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases","volume":"115","author":"Dang","year":"2020","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"2024062408262302200_goae069-B32","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cgh.2020.09.027","article-title":"Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","article-title":"Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study","volume":"74","author":"Marjot","year":"2021","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/joim.13545","article-title":"Increased mortality of patients with alcohol-related liver diseases during the COVID-19 pandemic in the United States","volume":"292","author":"Yeo","year":"2022","journal-title":"J Intern Med"},{"key":"2024062408262302200_goae069-B35","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.cgh.2022.05.045","article-title":"Trends in etiology-based mortality from chronic liver disease before and during COVID-19 pandemic in the United States","volume":"20","author":"Kim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B36","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study","volume":"393","author":"Manthey","year":"2019","journal-title":"Lancet"},{"key":"2024062408262302200_goae069-B37","doi-asserted-by":"crossref","first-page":"e316\u201323","DOI":"10.1016\/S2468-2667(20)30062-1","article-title":"Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019\u201340: a modelling study","volume":"5","author":"Julien","year":"2020","journal-title":"Lancet Public Health"},{"key":"2024062408262302200_goae069-B38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cld.1265","article-title":"Prospective clinical trials and novel therapies in the medical management of severe alcohol-associated hepatitis","volume":"20","author":"Pimienta","year":"2022","journal-title":"Clin Liver Dis"},{"key":"2024062408262302200_goae069-B39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2024062408262302200_goae069-B40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.17547","article-title":"Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2024062408262302200_goae069-B41","doi-asserted-by":"crossref","first-page":"14054","DOI":"10.1038\/s41598-021-92612-2","article-title":"The impact of the COVID-19 epidemic on hospital admissions for alcohol-related liver disease and pancreatitis in Japan","volume":"11","author":"Itoshima","year":"2021","journal-title":"Sci Rep"},{"key":"2024062408262302200_goae069-B42","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"2024062408262302200_goae069-B43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2013aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B45","author":"Health Organization"},{"key":"2024062408262302200_goae069-B46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"2024062408262302200_goae069-B48","first-page":"83","volume-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017"},{"key":"2024062408262302200_goae069-B49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B50","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","author":"Polaris Observatory Collaborators","year":"2024","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B54","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B55","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.jhepr.2022.100531","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep"},{"key":"2024062408262302200_goae069-B56","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jval.2020.06.015","article-title":"Cost-effectiveness of testing and treatment for hepatitis B virus and hepatitis C virus infections: an analysis by scenarios, regions, and income","volume":"23","author":"Tordrup","year":"2020","journal-title":"Value Health"},{"key":"2024062408262302200_goae069-B57","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/liv.15668","article-title":"Trends in mortality of liver cancer before and during the COVID-19 pandemic","volume":"43","author":"Kim","year":"2023","journal-title":"Liver Int"},{"key":"2024062408262302200_goae069-B58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3350\/cmh.2022.0316","article-title":"Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study","volume":"29","author":"Choi","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2024062408262302200_goae069-B59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3350\/cmh.2023.0092","article-title":"The current trends in the health burden of primary liver cancer across the globe","volume":"29","author":"Konyn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2024062408262302200_goae069-B60"},{"key":"2024062408262302200_goae069-B61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","article-title":"Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis","volume":"6","author":"Jin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B63","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3748\/wjg.v27.i29.4818","article-title":"New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years","volume":"27","author":"Dennis","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2024062408262302200_goae069-B64","doi-asserted-by":"crossref","first-page":"a036913","DOI":"10.1101\/cshperspect.a036913","article-title":"Hepatitis C virus epidemiology and the impact of interferon-free hepatitis C virus therapy","volume":"10","author":"Lazarus","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2024062408262302200_goae069-B65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2468-1253(20)30366-6","article-title":"The phases of hepatitis C elimination: achieving WHO elimination targets","volume":"6","author":"Pedrana","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J Hepatol"},{"key":"2024062408262302200_goae069-B67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(22)00010-3","article-title":"Interventions to eliminate hepatitis C: which ones suit your community?","volume":"7","author":"Wade","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B68","doi-asserted-by":"crossref","first-page":"e201997","DOI":"10.1001\/jamanetworkopen.2020.1997","article-title":"Trends in the burden of chronic liver disease among hospitalized US adults","volume":"3","author":"Hirode","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024062408262302200_goae069-B69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","article-title":"A model of the economic benefits of global hepatitis C elimination: an investment case","volume":"5","author":"Scott","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062408262302200_goae069-B70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40273-019-00864-8","article-title":"Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis","volume":"38","author":"Mattingly","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"2024062408262302200_goae069-B71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"2024062408262302200_goae069-B72","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.gastro.2018.07.008","article-title":"Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016","volume":"155","author":"Kim","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae069\/58310191\/goae069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae069\/58310191\/goae069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T08:27:04Z","timestamp":1719217624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae069\/7697717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae069","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae069"}}